Immunobiology of the HIV Envelope and its Relationship to Vaccine Strategies
One of the many bottlenecks standing before a rational approach to vaccine design against HIV is the lack of epidemiological evidence that immune responses to the virus are able to influence the course of infection or the disease process.
KeywordsCarbohydrate Cysteine Rosen Berman Paradis
Unable to display preview. Download preview PDF.
- Matthews TJ, Weinhold KJ, Lyerly HK, Langlois AJ, Wigzell J, Bolognesi DP: Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gpl20 and the surface antigen CD4: Role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci USA 1987; 84:5424–5428.PubMedCentralPubMedCrossRefGoogle Scholar
- Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, Berzofsky JA: Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gpl20 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987; 84:4249–4253.PubMedCentralPubMedCrossRefGoogle Scholar
- Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gpl60 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988; 85:3105–3109.PubMedCentralPubMedCrossRefGoogle Scholar
- Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ: Human T-cell lymphotropic virus HIB glycoprotein (gpl20) bound to CD4 determinants on normal lymphocytes and expressed by infected ceils serves as target for immune attack. Proc Natl Acad Sci USA 1987; 84:4601–4605.PubMedCentralPubMedCrossRefGoogle Scholar
- Ho DD, Li XL, Moudgil T, Alam M: HIV envelope domains important for antibody neutralization. In: Retroviruses of Human AIDS and Related Animal Diseases 1988; pp.155–158.Google Scholar
- Lee MR, Ho DD, Gurney ME: Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Science 237:1047–1051.Google Scholar
- Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, Bolognesi DP: HIV-1 gpl20-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immuno 1989; 142:3091–3097.Google Scholar
- Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman RL: Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Proc Natl Acad Sci USA 1985; 230:453–455.Google Scholar
- Klasse PJ, Pipkorn R, Blomberg J: Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc Natl Acad Sci USA 1988; 85:5225–5229.PubMedCentralPubMedCrossRefGoogle Scholar
- Robinson Jr. WE, Montefiori DC, Mitchell WM: Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (April) 1988; 790–794.Google Scholar
- Riviere Y, Tanneau-Salvadori F, Regnault A, Lopez O, Sansonetti P, Guy B, Kieny MP, Fournel JJ, Montagnier L: Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1989; 63:2270–2277.PubMedCentralPubMedGoogle Scholar